Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 121 of the 128 references it cites were found in a registry or an index; 143 of the 228 sources its claims cite were checked for support.

Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

Open access
Stefanoudakis, Dimitrios, Frountzas, Maximos, Schizas, Dimitrios, Michalopoulos, Nikolaos V., Drakaki, Alexandra, Toutouzas, Konstantinos G. · 2024 · Current Issues in Molecular Biology

Abstract

Review of major molecular alterations in pancreatic cancer.

Overview

CoChat Summary

TL;DR

This is a narrative review of the roles of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer, emphasizing how their alterations shape tumor biology, prognosis and potential targeted treatment strategies. It argues that molecular profiling can support risk assessment, early detection and more personalized therapy, but also shows that many of these biomarkers still need further validation.

Key findings

  • TP53 mutations are reported in 50–90% of pancreatic ductal adenocarcinomas and in 60–70% of cases in another section; they are linked to carcinogenesis, chemotherapy resistance and prognosis. TP53 mutations were also reported across pancreatic lesions, from 9.1% of intermediate-grade IPMNs to 75% of invasive ductal adenocarcinomas.
  • CDKN2A alterations are described as common and clinically relevant: somatic mutations are reported in up to 95% of pancreatic tumors, and in TCGA analysis patients with CDKN2A mutations or deep deletions had poorer overall survival and primary therapy outcomes. The paper also states that CDKN2A-inactivated PDAC showed increased sensitivity to paclitaxel and SN-38.
  • SMAD4/DPC4 loss is repeatedly associated with worse outcomes and metastasis. In one PDAC cohort of 249 patients, 43% lacked SMAD4 expression and 45% were positive; intact SMAD4 expression was associated with median survival of 19.2 months versus 14.7 months without SMAD4. In another cohort of 348 PDAC patients, 53% had DPC4/Smad4 expression loss.
  • KRAS is the most frequently mutated gene in pancreatic cancer, reported at 90–95% in pancreatic adenocarcinomas and near 100% in PDAC in one section. The review also notes studies where KRAS mutations were found in 74.7% of EUS-FNA samples and 62.6% of ctDNA samples, and that ctDNA KRAS mutations were associated with shorter median survival.

Methods

  • Narrative review of published studies on the molecular biology, prognosis and therapeutic targeting of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer.
  • The paper synthesizes findings from human cohorts, TCGA/bioinformatics analyses, liquid biopsy studies, and preclinical mouse/cell line experiments.
  • Main analysis is qualitative integration of reported mutation frequencies, survival associations, and treatment-response observations across the cited literature.

Limitations

  • The paper does not describe a systematic review protocol, search strategy, inclusion criteria, or meta-analysis; this is evident from the text.
  • The review itself notes that the prognostic impact of some markers remains unsettled, e.g. CDKN2A mutations are “still being investigated” and the impact on treatment response “requires further exploration.”
  • It also states that SMAD4 effects on chemotherapy response may vary by treatment regimen and disease stage, indicating incomplete or context-dependent evidence.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cimb46040177

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Modifiable factors include smoking, alcohol, obesity and dietary factors, where red meat increases risk, while vegetables and fruits offer protection. Non-modifiable risk factors comprise gender, age (with increased risk after 50), ethnicity, diabetes, family history, genetic factors, chronic infections and ABO blood group (non-O associated with higher risk). Created with BioRender.com (accessed on 27 February 2024) [13].
Figure 1 Modifiable factors include smoking, alcohol, obesity and dietary factors, where red meat increases risk, while vegetables and fruits offer protection. Non-modifiable risk factors comprise gender, age (with increased risk after 50), ethnicity, diabetes, family history, genetic factors, chronic infections and ABO blood group (non-O associated with higher risk). Created with BioRender.com (accessed on 27 February 2024) [13].CC BY · PubMed Central
Figure 2 Schematic representation of the mode of action of TGF-β on cytoplasmic membrane receptors as well as the action of SMAD 4-SMAD 2/3 complex on intranuclear target genes: TGF-β binds to cytoplasmic membrane receptors, triggering downstream signaling cascades. One key pathway involves the formation of a SMAD4-SMAD2/3 complex, which translocates into the nucleus and regulates the expression of target genes, influencing various cellular processes. This mechanism illustrates how TGF-β signaling via SMAD proteins modulates gene expression and cellular responses. Created with BioRender.com (accessed on 27 February 2024).
Figure 2 Schematic representation of the mode of action of TGF-β on cytoplasmic membrane receptors as well as the action of SMAD 4-SMAD 2/3 complex on intranuclear target genes: TGF-β binds to cytoplasmic membrane receptors, triggering downstream signaling cascades. One key pathway involves the formation of a SMAD4-SMAD2/3 complex, which translocates into the nucleus and regulates the expression of target genes, influencing various cellular processes. This mechanism illustrates how TGF-β signaling via SMAD proteins modulates gene expression and cellular responses. Created with BioRender.com (accessed on 27 February 2024).CC BY · PubMed Central
Figure 3 Diagrammatic presentation of the KRAS pathway: The KRAS pathway, including PI3K, RAF and RAL, operates synergistically to regulate key cellular processes such as proliferation, survival and metabolism. Upon activation by extracellular signals, KRAS initiates a signaling cascade that involves the activation of PI3K, RAF and RAL proteins. These downstream effectors act in concert to propagate signaling, leading to the activation of various pathways involved in cell growth and survival. Dysregulation of this synergistic network, often through mutations in KRAS or its effectors, contributes to cancer development and progression. Created with BioRender.com (accessed on 27 February 2024).
Figure 3 Diagrammatic presentation of the KRAS pathway: The KRAS pathway, including PI3K, RAF and RAL, operates synergistically to regulate key cellular processes such as proliferation, survival and metabolism. Upon activation by extracellular signals, KRAS initiates a signaling cascade that involves the activation of PI3K, RAF and RAL proteins. These downstream effectors act in concert to propagate signaling, leading to the activation of various pathways involved in cell growth and survival. Dysregulation of this synergistic network, often through mutations in KRAS or its effectors, contributes to cancer development and progression. Created with BioRender.com (accessed on 27 February 2024).CC BY · PubMed Central

Verification

Claims the paper makes

106 Valid · 3 Not valid · 52 Not checked · 2 Own results and interpretations

66 more claims · 39 with their cited sources checked

Create a free account to see all 163 claims and to verify the 24 references still open.

See all claims — free account
  • It may state two separate claims as one. 88
  • Borderline: one of the tests for a substantial claim is unclear. 1
  • Probably not a substantial claim. 4

Create a free account to see these claims.

Citations

Cites

Show all 128 references

Research works printed but not linked: 2

  1. (2023, December 26). CDKN2A Cyclin Dependent Kinase Inhibitor 2A [Homo Sapiens (Human)], Available online: https://www.ncbi.nlm.nih.gov/gene/1029.
  2. Lovely, 2023, Explorations Unearth New Potential of KRAS Mutations in Pancreatic Cancer, Oncol. Live, 24, 12

Cited by

See all 110

Metadata

Authors
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G.
Affiliations
  • National and Kapodistrian University of Athens (GR)
  • First Department of Surgery, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
  • University of California, Los Angeles (US)
Corresponding author
Toutouzas, Konstantinos G.
Venue
Current Issues in Molecular Biology
Publisher
MDPI AG
Published
2024-03-23
Volume
46
Issue
4
Pages
2827-2844
ISSN
  • 1467-3037 (ISSN-L)
  • 1467-3045
OpenAlex
W4393164529
Cited by
110
References
128
Citations by year
2026: 55 · 2025: 42 · 2024: 13
FWCI
5.88
Type
journal article
Language
en
Open access
Locations
  • Current Issues in Molecular Biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
pancreatic cancer, TP53, CDKN2A, SMAD4, KRAS, tumor suppressor, p53 deficiency, prognostic value, targeted therapy, molecular signatures, cancer risk assessment, early detection, personalized treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. https://app.cochat.ai/papers/10.3390/cimb46040177
The paper
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024). Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. Current Issues in Molecular Biology. https://doi.org/10.3390/cimb46040177

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.